Geniposide Mitigates Insulin Resistance and Hepatic Fibrosis via Insulin Signaling Pathway

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Geniposide improves insulin resistance and hepatic fibrosis in mice with high-fat diet-induced NASH, suggesting novel therapeutic applications.

Geniposide treatment significantly reduces insulin resistance and hepatic fibrosis in a mouse model of NASH, showing promise for metabolic disorders.
After 12 weeks, GP treatment improved glucose metabolism metrics, including insulin sensitivity and blood lipid profiles in treated mice.
Analysis included histological examinations and gene expression studies showing modulation of inflammation and insulin signaling pathways by geniposide.
These findings imply that geniposide may offer a therapeutic option for conditions related to type 2 diabetes and liver diseases.

Oh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Geniposide improves insulin resistance and hepatic fibrosis in mice with high-fat diet-induced NASH, suggesting novel therapeutic applications.